Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Apr 2021

Bardia Aditya, Kaklamani Virginia, Wilks Sharon, Weise Amy, Richards Donald, Harb Wael, Osborne Cynthia, Wesolowski Robert, Karuturi Meghan, Conkling Paul, Bagley Rebecca G, Wang Yamei, Conlan Maureen G, Kabos Peter

Abstract excerpt

PURPOSE: This phase I study (RAD1901-005; NCT02338349) evaluated elacestrant, an investigational oral selective estrogen receptor degrader (SERD), in heavily pretreated women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer, including those with estrogen receptor gene alpha (ESR1) mutation. The primary objective was to determine the maximum tolerated dose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Estrogen Receptor alpha

Share to Mutation

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Source

Open in PubMed Open full text

Identifiers

PMID: 33513026
DOI: 10.1200/JCO.20.02272
PMCID: PMC8078341

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.PMID 33513026Read ↗

Elacestrant in metastatic breast cancer: current advancements and future perspectives.Semantic proximity Read ↗

Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title.Semantic proximity Read ↗

Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.Semantic proximity Read ↗

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.Semantic proximity Read ↗

Oral SERD, A Novel Endocrine Therapy for Estrogen Receptor-Positive Breast CancerSemantic proximity Read ↗

A Novel Oral Selective Estrogen Receptor Degrader TFX06 Suppresses In Vivo Growth of ESR1 Wild-Type and Mutant TumorsSemantic proximity Read ↗

Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer.Semantic proximity Read ↗

The Value of Oral Selective Estrogen Receptor Degraders in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer after Progression on ≥ 1 Line of Endocrine Therapy: Systematic Review and Meta-analysisSemantic proximity Read ↗

Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.Semantic proximity Read ↗

Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.Semantic proximity Read ↗

Design of SERENA-6, a phase III switching trial of camizestrant in ESR1 -mutant breast cancer during first-line treatmentSemantic proximity Read ↗

Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.